RCM
HTGM

Requisite Capital Management’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Requisite Capital Management’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-556
Closed -$254K – 224
2018
Q4 		$254K Buy
+556
New +$345K 0.1% 52

Other funds holding HTGM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Requisite Capital Management's HTGM Position: Q1 2019 in Review

Requisite Capital Management sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q1 2019, closing a stake of 556 shares — an estimated $254K sold.

Requisite Capital Management first reported a position in HTGM in Q4 2018 and held it in 1 quarter. The position peaked at $254K in Q4 2018. 39 funds tracked by Wall St. Rank hold HTGM as of Q1 2019.

  • Requisite Capital Management reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Requisite Capital Management sold 556 HTG Molecular Diagnostics, Inc. Common Stock shares in Q1 2019, an estimated $254K.
  • Requisite Capital Management first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q4 2018 and held it in 1 quarter.
  • Requisite Capital Management's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $254K in Q4 2018.
  • 39 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q1 2019.

Based on Requisite Capital Management's 13F filing for Q1 2019, filed 15 May 2019.